Shared on 02 Nov 25
Fair value Decreased 1.70%Narrative Update on Royalty Pharma: Analyst Price Target Revision Analysts have lowered their fair value estimate for Royalty Pharma from $44.86 to $44.10 per share. This revision is based on updated modeling of revenue growth and profit margins.
Shared on 04 Sep 25
Fair value Increased 3.66%Emerging Therapies And Licensing Will Expand Royalty Opportunities
Analysts maintain a positive outlook for Royalty Pharma, citing resilience amid sector underperformance, limited exposure to policy and macroeconomic risks, and anticipated seasonal strength, with the consensus price target unchanged at $43.27. Analyst Commentary Bullish analysts expect Q2 to be seasonally strong for large biopharma companies, supporting near-term performance.
Shared on 07 May 25
Fair value Decreased 20%Emerging Therapies And Licensing Will Expand Royalty Opportunities
Shared on 30 Apr 25
Fair value Increased 0.74%Integration Will Generate Over $100 Million In Savings By 2026
AnalystConsensusTarget has increased profit margin from 29.9% to 51.0% and decreased future PE multiple from 26.2x to 15.2x.
Shared on 23 Apr 25
Fair value Decreased 1.46%Integration Will Generate Over $100 Million In Savings By 2026
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 16 Apr 25
Fair value Decreased 2.16%Integration Will Generate Over $100 Million In Savings By 2026
AnalystConsensusTarget has decreased revenue growth from 12.5% to 10.8%.
Shared on 09 Apr 25
Integration Will Generate Over $100 Million In Savings By 2026
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 2.85%Integration Will Generate Over $100 Million In Savings By 2026
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Integration Will Generate Over $100 Million In Savings By 2026
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Integration Will Generate Over $100 Million In Savings By 2026
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Increased 30%Integration Will Generate Over $100 Million In Savings By 2026
AnalystConsensusTarget has increased revenue growth from 7.2% to 12.5%, decreased profit margin from 36.7% to 28.6% and increased future PE multiple from 21.5x to 27.2x.